Medical Research News
Focus on the latest clinical studies, reports, findings, programs and standards covering a wide spectrum of medical and health issues. This section highlights research into human populations and includes information about research facilities, funding, resources and public policy.
Pennington Biomedical Researcher Dr. Emily Flanagan Launching Study on Infant Energy Balance and Early-Life Growth
First-of-its-kind study examining how energy intake and expenditure influence infant growth and future obesity risk. - September 05, 2026 - Pennington Biomedical Research Center
Pennington Biomedical Researchers Find Peroxisomes Help Protect Insulin and Maintain Beta Cell Health
Study reveals impaired peroxisomal function can increase insulin secretion while promoting insulin oxidation and disrupting pancreatic beta cell maturity. - September 03, 2026 - Pennington Biomedical Research Center
Beyond the Scale: Emerge Weight Loss Expands GLP-1 Telehealth Care to Support Women Living With PCOS and Endometriosis
As emerging research illuminates tirzepatide's metabolic and anti-inflammatory effects, Emerge extends compassionate, medically supervised weight loss care from board-certified providers to women whose health needs reach far beyond a number on the scale. - September 02, 2026 - Emerge Weight Loss, LLC
Helix BioMedix Completes $2 Million Private Placement to Advance Xeroderma Pigmentosum Development Program
Financing strengthens balance sheet and accelerates advancement of proprietary DNA repair technology targeting UV-induced DNA damage. - August 29, 2026 - Helix BioMedix, Inc
Pennington Biomedical’s 2026 Childhood Obesity Conference: “Be the Reason Kids Greaux Healthy” to be Held Sept. 24
Event brings together healthcare professionals, researchers, educators and community leaders to explore strategies for preventing and treating childhood obesity. - August 27, 2026 - Pennington Biomedical Research Center
Pennington Biomedical's Dr. Steven Heymsfield Co-Authors Editorial Highlighting the Unanticipated Benefits of GLP-1 Medications
Dr. Steven Heymsfield and Dr. Adam Gilden’s Obesity journal editorial highlights emerging benefits and questions surrounding this rapidly expanding class of medications - August 26, 2026 - Pennington Biomedical Research Center
Four Peer-Reviewed Clinical Study Publications Build a Substantial Evidence Base for Oxaloacetate CFS in ME/CFS and Long COVID
Research published in the Journal of Translational Medicine, Frontiers in Neurology and Frontiers in Neuroscience journals finds oxaloacetate improves ME/CFS and Long COVID symptoms including physical fatigue, mental fatigue, cognition, symptom burden and upright activity. - August 18, 2026 - Terra Biological LLC
New 2026 Report Reveals an AI/LLM Gap Between Biopharma Sponsors and Their CROs/Vendors
Life Science Strategy Group looks beyond frontier-AI hype to show how biopharma teams use AI and LLMs in daily work, and where their CRO and vendor partners are falling short. 71% of sponsors rate their own AI/LLM output highly. Only 27% say the same of their CROs and vendors. - August 12, 2026 - Life Science Strategy Group, LLC
ecotera health Submits Decentralized Urine Microplastics / Nanoplastics Observational Study for IRB Review
Study will evaluate an at-home approach to longitudinal microplastics / nanoplastics monitoring in urine using the EcoExposure™ platform - August 08, 2026 - ecotera health
New Approach to Obesity Classification Could Better Guide Treatment Decisions
Pennington Biomedical researchers examine limitations of “metabolically healthy obesity” and support a framework that connects treatment to organ dysfunction. - August 02, 2026 - Pennington Biomedical Research Center
Pennington Biomedical Researchers Part of National Study Showing Proven Childhood Obesity Treatment Also Works at Pediatrician’s Office
Family-based treatment helped nearly half of kids in clinical trial reach healthier weight - July 31, 2026 - Pennington Biomedical Research Center
Microvascular Therapeutics Highlights the Future of Ultrasound Theranostics in Comprehensive Wiley Review
Microvascular Therapeutics, Inc. (MVT) today announced publication of a comprehensive review in Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology (WIREs Nanomedicine and Nanobiotechnology), a leading peer-reviewed journal with a 2025 Journal Impact Factor of 8.6, entitled,... - July 28, 2026 - Microvascular Therapeutics, Inc.
Pennington Biomedical Researchers to Present at NUTRITION 2026
Researchers will contribute to sessions focused on organoid models, GLP-1 therapies, protein intake, early-life nutrition, vitamins and minerals, artificial intelligence and more. - July 27, 2026 - Pennington Biomedical Research Center
Biomarker Discovery by Pennington Biomedical and Colleagues Could Advance Treatments for Obesity-Related Health Risks
Study published in Metabolism identifies endotrophin as dynamic marker of changes in body fat and metabolic health - July 25, 2026 - Pennington Biomedical Research Center
Pennington Biomedical, Our Lady of the Lake and Metamor Institute Show Promising Outcomes for Bariatric Surgery in Adolescents and Young Adults with Severe Obesity
Research collaboration highlights safe surgical outcomes and significant health improvements in young patients in Louisiana - July 15, 2026 - Pennington Biomedical Research Center
Clinical Based Evidence of Eminent Spine's 3D Printed Titanium Pedicle Screw
Eminent Spine, a leader in advanced 3D implant technology, releases the early clinical and implant results of the world's first FDA 510(k) approved 3D printed titanium pedicle screw. The proprietary 3D printed pedicle screw, designed and manufactured by Eminent Spine received FDA 501(k) clearance... - July 14, 2026 - Eminent Spine
Pennington Biomedical's Dr. Tim Allerton Studying a New Approach to Advance Heart Failure Research
Dr. Allerton to research one of the fastest-growing forms of heart failure - July 13, 2026 - Pennington Biomedical Research Center
Pennington Biomedical Releases RURAL Health Study's Key Drivers of Chronic Disease in Franklin Parish, Louisiana
Franklin Parish data now available to go along with Assumption Parish data revealed earlier this year from Pennington Biomedical. - July 07, 2026 - Pennington Biomedical Research Center
Hemanext Expands Commercial Footprint Through Strategic Partnership with OneBlood
Hemanext Inc. announced a strategic production partnership with OneBlood, one of the nation's largest independent blood centers, marking a significant milestone in Hemanext's commercial expansion and accelerating adoption of Hemanext ONE® across the United States. - July 06, 2026 - Hemanext
New York Cancer & Blood Specialists Welcomes Medical Oncologist-Hematologist, Dr. Neel Patel
New York Cancer & Blood Specialists (NYCBS), one of the Nation’s leading oncology practices, proudly announces the addition of Dr. Neel Patel, a hematologist-oncologist dedicated to providing evidence-based, compassionate cancer care. Beginning July 1, 2026, Dr. Patel will be practicing... - July 04, 2026 - New York Cancer & Blood Specialists
Microvascular Therapeutics to Present Late-Breaking Clinical Data on CardiSon™ (MVT-100) at the 2026 American Society of Echocardiography Meeting.
Clinical Study Demonstrates Superior Left Ventricular Opacification and Significantly Reduced Acoustic Shadowing Compared with Definity®. - June 26, 2026 - Microvascular Therapeutics, Inc.
The Methodist University Cape Fear Valley Health School of Medicine, N.C.’s Newest Med School, Holds Ribbon-Cutting Ceremony
Forever changing the future of healthcare in Southeastern North Carolina, the new School of Medicine (SOM) was announced in 2023 through a partnership between MU and Cape Fear Valley Health and the ribbon cutting helped signify once again how the dream has truly become the reality. - June 24, 2026 - Methodist University
Hundreds of Cyclists to Ride Across Three States to Advance ALS Research
More than 400 cyclists, volunteers, and supporters will gather in Durham, New Hampshire on June 27–28 for the 24th annual Tri-State Trek, a two-day cycling event benefiting the ALS Therapy Development Institute (ALS TDI), the world's most comprehensive drug discovery institute dedicated... - June 23, 2026 - ALS Therapy Development Institute
Pennington Biomedical Recruiting Participants for Study on Weight Loss Using GLP-1-Based Therapy
Led by LSU Boyd Professor Dr. Eric Ravussin, the Novo Expenditure trial examines a hormone-based investigational treatment and its effects on energy use and weight loss - June 18, 2026 - Pennington Biomedical Research Center
Pennington Biomedical Seeks Volunteers for Study on How the Body Regulates Weight
Study to explore how energy intake, energy expenditure and biological responses interact to influence body weight - June 18, 2026 - Pennington Biomedical Research Center
Dr. Owen Carmichael Awarded James W. and Neil Ann Parks Professorship for Dementia Research, Prevention and Treatment at Pennington Biomedical
Dr. Carmichael's research focuses on developing and applying advanced biomedical imaging techniques to better understand Alzheimer’s disease, dementia, brain aging and the effects of lifestyle and metabolic health on cognitive decline - June 18, 2026 - Pennington Biomedical Research Center
Pennington Biomedical Recruiting Adults with Type 2 Diabetes for Avocado Nutrition Study
Researchers to examine whether daily avocado consumption can improve blood sugar control and insulin sensitivity. - June 18, 2026 - Pennington Biomedical Research Center
MyConcussionDR Announces Public Support for the American Center for Cures
Brain health education team joins national initiative to fund the prevention and cure of major diseases, citing its shared commitment to families, accountability, and long-term neurological health. - June 08, 2026 - MyconcussionDR
NuRev Wholesale Launches Dedicated Platform for Wholesale Research Peptide Procurement
New Wholesale Program Designed to Support Laboratories, Research Organizations, Distributors, and Qualified Business Buyers - June 07, 2026 - NuRev Wholesale
Alera Bio Appoints David McCullough as Chief Executive Officer
Alera Bio announced the appointment of David McCullough as Chief Executive Officer. An experienced biotechnology executive, McCullough will lead corporate strategy, financing, organizational development, and execution of the company’s clinical and regulatory roadmap. He will oversee advancement of AB-101, Alera’s novel therapy for MCT-8 deficiency, as the company works to bring new hope to patients and families affected by this devastating rare neurodevelopmental disorder. - June 04, 2026 - Alera Bio
New York Cancer & Blood Specialists Welcomes Medical Oncologist-Hematologist, Dr. Shuwen Lin
New York Cancer & Blood Specialists (NYCBS), one of the nation’s leading oncology practices, proudly announces the addition of Dr. Shuwen Lin, a board-certified hematologist-oncologist dedicated to providing evidence-based, compassionate cancer care. Beginning June 1, 2026, Dr. Lin will... - June 03, 2026 - New York Cancer & Blood Specialists
LSU's Pennington Biomedical Research Center Names 2025 Publication of the Year
Dr. Carmichael’s award-winning publication represents a landmark contribution to obesity research and translational medicine. - May 30, 2026 - Pennington Biomedical Research Center
Pennington Biomedical: New International Study Highlights Impact of Restrained Sitting on Movement Behaviors in Young Children
Researchers explored how time spent restrained in devices such as car seats and strollers may influence children's ability to meet movement behavior recommendations - May 30, 2026 - Pennington Biomedical Research Center
SPARK Industries Announces New MRI Signal Analysis Platform for Neurological Disease and Cancer Research
SPARK Industries announced advancements in its patent-pending MRI signal-analysis platform designed to detect previously unresolved neurological and structural signatures within raw MRI data. Internal validation across 1,000+ clinical MRI cases involving TBI, Alzheimer’s, Parkinson’s, and prostate cancer demonstrated consistent signal relationships associated with known disease states. SPARK is now pursuing blinded third-party validation trials. - May 27, 2026 - SPARK Industries Corporation
KŪR Health Acquires Key Assets and Technology from Catbird Health to Advance AI-Powered Trauma Recovery
KŪR Health announced the acquisition of key assets, intellectual property, and select talent from Catbird Health, combining clinical trauma research infrastructure with AI-powered personalized healing technology. Together, the companies aim to pioneer a new trauma-responsive healthcare model addressing the biological, neurological, and behavioral roots of chronic disease through personalized, preventative, and nervous system-informed care. - May 21, 2026 - Kur Health
O∆K Names Sarp Sahin 2026 National Leader of the Year for Academics and Research
Sarp Sahin Awarded 2026 Omicron Delta Kappa National Leader of the Year for Academics and Research - May 20, 2026 - Omicron Delta Kappa
Pennington Biomedical Contributes to Global Study on Physical Activity and Well-Being
Study offers new insight into how physical activity and emotional well-being are connected in everyday life. - May 13, 2026 - Pennington Biomedical Research Center
Critical Role of Exercise in the GLP-1 Era: Pennington Biomedical and Harvard Perspective
JAMA-published perspective by authors Dr. Steven Heymsfield of Pennington Biomedical and Drs. Daniel Lieberman and Daniel Aslan of Harvard University. - May 09, 2026 - Pennington Biomedical Research Center
Pennington Biomedical Convenes Global Experts to Advance Understanding of Ultra-Processed Foods and Health
Symposium co-chaired by LSU Boyd Professor Dr. Eric Ravussin and University of Auckland’s Dr. Boyd Swinburn, both internationally recognized leaders in metabolism and public health nutrition - May 06, 2026 - Pennington Biomedical Research Center
Dr. Hannah Cabré Appointed Assistant Professor and Director of the Aging, Gynecology, and Endocrinology Laboratory at Pennington Biomedical
LSU’s Pennington Biomedical Research Center is pleased to announce the appointment of Dr. Hannah Cabré as an Assistant Professor, effective May 1. Dr. Cabré, an emerging leader in the field of nutrition, aging and women’s health, will lead the newly established Aging,... - May 06, 2026 - Pennington Biomedical Research Center
Pennington Biomedical Research Advances Understanding of How the Brain Senses Diet to Control Appetite and Metabolism
Research published in Cell Reports identifies liver-to-brain signals regulating eating and energy use. - April 26, 2026 - Pennington Biomedical Research Center
Minutes Matter Most When Exercising to Control Blood Sugar
Study says longer, not stronger, is the key for people with Type 2 diabetes. - April 10, 2026 - Pennington Biomedical Research Center
Alera Bio Announces Exclusive Licensing Agreement with BLA Technology to Expand Thyroid Hormone Intellectual Property Portfolio
Alera Bio has secured an exclusive global license from BLA Technology, LLC for thyroid hormone-related IP, strengthening its platform for MCT-8 deficiency. The deal expands Alera’s ability to target both neurological and systemic disease drivers, supports its lead program AB-101, reduces development risk, and enables future pipeline growth. - April 09, 2026 - Alera Bio
Alera Bio Appoints Andrew Eisen, MD, PhD, as Chief Scientific Officer
Alera Bio has appointed Andrew Eisen, MD, PhD, as Chief Scientific Officer, bringing over 20 years of experience in translational medicine and clinical development. With deep expertise in neuroscience, metabolic disease, and myelination, Dr. Eisen will lead the advancement of Alera’s lead program, AB-101, and help drive its mission to develop transformative therapies for patients with severe neurological disorders, including MCT-8 deficiency. - April 08, 2026 - Alera Bio
Life's Essential 8: Optimizing Lifestyle Factors to Reduce Cardiometabolic Risk and Improve Cardiovascular Health
Chinese Medical Journal Review: Lifestyle Factors and Cardiometabolic Risk - April 01, 2026 - Pennington Biomedical Research Center
PRISM ALS: New Stem Cell Models Could Transform Research Into Treatments for MND/ALS
PRISM ALS is a new global initiative designed to accelerate the discovery of effective treatments for ALS/MND by improving access to specially grown, patient-derived stem cell models that better reflect the biological diversity of the disease. - March 31, 2026 - ALS Therapy Development Institute
SignaBlok Receives Orphan Drug Designation from FDA for a First-in-Class TREM-1 Peptide Inhibitor for the Treatment of Retinopathy of Prematurity
SignaBlok, Inc., a preclinical stage biotechnology company pioneering novel, first-in-class peptide therapies for multiple inflammation-associated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s TREM-1 peptide... - March 27, 2026 - SignaBlok, Inc.
Medical Industry Websites Compete for Digital Excellence in the WebAwards
The Web Marketing Association has opened entries for the 30th Annual WebAward Competition, inviting hospitals, medical practices, and healthcare organizations worldwide to compete for recognition as the best medical websites of 2026. Websites will be evaluated on design, innovation, usability, and technology. Winners gain industry recognition and valuable benchmarking insights. Entry deadline: May 29, 2026. - March 27, 2026 - Web Marketing Association
SignaBlok to Present Novel Approach to Preventing Cancer Recurrence at the 2026 American Association for Cancer Research (AACR) Annual Meeting
• In experimental pancreatic cancer, macrophage-targeted but not cell-unspecific TREM-1 inhibitor: 1) prevents cancer recurrence, improves complete response rate and survival, when administered in a time window of 7 days after standard-of-care (SOC) chemotherapy, and 2) reverses immunosuppression and overcomes cancer resistance to anti-PD-L1 immunotherapy - March 26, 2026 - SignaBlok, Inc.
RURAL Health Study Reveals Key Drivers of Chronic Disease in Assumption Parish
The study is evaluating health outcomes in comparable rural parishes; Assumption Parish data revealed with Franklin Parish data to follow later this year. - March 22, 2026 - Pennington Biomedical Research Center